A5089888839- PI3K/AKT/mTOR signaling in cancer
- Chemotherapy-induced organ toxicity mitigation
- Lung Cancer Treatments and Mutations
- Ovarian cancer diagnosis and treatment
- Lymphoma Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Neuroblastoma Research and Treatments
- LGBTQ Health, Identity, and Policy
- Neuroendocrine Tumor Research Advances
- Sex and Gender in Healthcare
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Research Studies
- BRCA gene mutations in cancer
Cancer Genetics (United States)
2023
University of California, San Francisco
2021-2023
4148 Background: The efficacy of immune checkpoint inhibitor (CPI) therapy has not been established in extrapulmonary poorly differentiated neuroendocrine carcinomas (EP-PDNECs). In small cell lung cancer, CPI is approved for use the first-line and salvage settings. We investigated safety pembrolizumab (PEM)-based biomarker-unselected patients (pts) with EP-PDNECs. PEM alone (Part A, N=14) was inactive (ASCO GI 2019; Abstr#363). now report results Part B (PEM plus chemotherapy). Methods:...
Germline testing for men with prostate cancer (PCa) poses numerous implementation barriers. Alternative models of care delivery are emerging, but outcomes understudied. We evaluated a hybrid oncologist- and genetic counselor-delivered model called the station (GTS) created to streamline increase access.A prospective, single-institution, cohort study PCa referred GTS from October 14, 2019, 2021, was conducted. Using Reach, Effectiveness, Adoption, Implementation, Maintenance framework, we...
The PI3K pathway may be a potential mechanism to overcome cisplatin resistance. We conducted phase Ib trial of alpelisib and for patients with solid tumor malignancies planned dose expansion in HPV-associated tumors. primary objective was determine the MTD recommended II dose. Two different weekly doses (30 35 mg/m2) were evaluated escalating alpelisib, administered daily during 21-day treatment cycle. Twenty-three enrolled: 91% received >3 prior regimens median 4 (range 1–10), 78%...
<div><p>The PI3K pathway may be a potential mechanism to overcome cisplatin resistance. We conducted phase Ib trial of alpelisib and for patients with solid tumor malignancies planned dose expansion in HPV-associated tumors. The primary objective was determine the MTD recommended II dose. Two different weekly doses (30 35 mg/m<sup>2</sup>) were evaluated escalating alpelisib, administered daily during 21-day treatment cycle. Twenty-three enrolled: 91% received >3...
<div><p>The PI3K pathway may be a potential mechanism to overcome cisplatin resistance. We conducted phase Ib trial of alpelisib and for patients with solid tumor malignancies planned dose expansion in HPV-associated tumors. The primary objective was determine the MTD recommended II dose. Two different weekly doses (30 35 mg/m<sup>2</sup>) were evaluated escalating alpelisib, administered daily during 21-day treatment cycle. Twenty-three enrolled: 91% received >3...
3134 Background: The PI3K pathway may represent a mechanism to overcome cisplatin resistance, particularly in human papilloma virus (HPV)-associated tumors. We conducted phase Ib trial of alpelisib and for patients with solid tumor malignancies HPV-associated tumors the dose expansion cohort. Methods: Patients advanced were enrolled this open label study (NCT02620839). Dose escalation followed standard 3+3 design. Two different weekly doses (30 35 mg/m 2 ) evaluated escalating alpelisib,...